De Chiara G, et al. (2006) Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem 281, 21353-61 16714293

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T56-p - Bcl-2 (human) ▲

Modsite: FSSQPGHtPHPAASR SwissProt Entrez-Gene Orthologous residues Bcl‑2 (human): T56‑p, Bcl‑2 (mouse): N56‑p, Bcl‑2 (rat): N56‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  CESS (lymphoblastoid), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE P38A (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE P38A (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes K252a increase SB203580 K252a inhibit treatment-induced increase Downstream Regulation Effect of modification (process):  apoptosis, induced

S87-p - Bcl-2 (human) ▲

Modsite: AAAGPALsPVPPVVH SwissProt Entrez-Gene Orthologous residues Bcl‑2 (human): S87‑p, Bcl‑2 (mouse): S84‑p, Bcl‑2 (rat): S84‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  CESS (lymphoblastoid), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE P38A (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE P38A (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes K252a increase SB203580 K252a inhibit treatment-induced increase Downstream Regulation Effect of modification (process):  apoptosis, induced